Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury

Core Insights - Tiziana Life Sciences Ltd is highlighted as one of the best biotech penny stocks to invest in currently [1] Company Overview - Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer's, and multiple system atrophy [2] Management Activity - In September 2025, significant insider activity was noted, with CEO Ivor Elrifi purchasing 193,848 shares at $1.65 each, and Executive Chairman Gabriele Cerrone acquiring 25,000 shares, increasing his stake to 36.28%, indicating strong management confidence in the company's pipeline and long-term prospects [3] Recent Developments - Tiziana Life Sciences Ltd secured a U.S. Department of Defense grant on September 15, 2025, to advance the development of intranasal foralumab for spinal cord injury, expanding its focus beyond central nervous system disorders [4] - The company achieved a milestone by dosing the first patient in a Phase 2a trial for multiple system atrophy, following FDA approval of a Phase 2 IND application in August 2025 [4]